Anticoagulative efficacy of argatroban and heparin in maintenance hemodialysis patients

Abstract

Objective To compare the therapeutic effect and safety of argatroban and heparin on patients receiving anticoagulant therapy during hemodialysis. Methods A total of 40 patients were received anticoagulant therapy during their hemodialysis, once given argatroban, and once given heparin. According to different anticoagulant drugs used on them, the activated partial thromboplastin time (APTT) was detected before and after hemodialysis. Coagulation within the pipeline and filter was observed during treatment.The mean hemostatic time of puncture point compression and bleeding events (including nose bleeding, gum bleeding, conjunctival bleeding, mucocutaneous hemorrhage and hematochezia, etc.) within 24 h after treatment were also detected. Results APTT in argatroban group was significantly prolonged during hemodialysis treatment compared with predialysis, the difference was statistically significant (P 0.05). The mean hemostatic time of puncture point compression in the heparin group obvious longer than the argatroban group (P<0.01). The incidence of bleeding events of tissue and apparatus in the heparin group obvious frequently than the argatroban group (P<0.05). Conclusion Argatroban is effective for patients receiving anticoagulant therapy during hemodialysis, which may have less negative influence on the hemorrhage. It is safety to be used on patients with high risk of hemorrhage during hemodialysis. Key words: Argatroban; Heparin; Hemodialysis; Anticoagulation